Dayvigo Cost in Wisconsin 2026: Prices, Insurance, Medicaid, and Compounding Options

What Dayvigo Actually Costs in Wisconsin in 2026

The Eisai wholesale acquisition price for Dayvigo sits at roughly $320 per 30-tablet supply. That number applies whether you fill a prescription for lemborexant 5 mg or lemborexant 10 mg. At Wisconsin retail pharmacies, the cash price without any coupon typically tracks close to that list figure, because Dayvigo has no FDA-approved generic as of 2026.

Discount programs change the picture substantially. GoodRx, RxSaver, and similar pharmacy benefit managers routinely bring the Wisconsin cash price down to approximately $85 per month at chains including Walgreens, CVS, Walmart Pharmacy, and Costco. The exact figure varies by ZIP code, pharmacy contract, and the specific discount program version in use at the time of dispensing, so always run a real-time query at the pharmacy counter before paying. The FDA's Orange Book confirms lemborexant remains single-source branded as of the current edition.

The FDA approved Dayvigo on August 23, 2019, for treatment of insomnia characterized by difficulties with sleep onset or sleep maintenance in adults. The Dayvigo prescribing information specifies a starting dose of 5 mg, with an option to increase to 10 mg if the 5 mg dose is tolerated but not sufficiently effective. Both strengths carry the same retail price tier.

How Wisconsin Medicaid Covers Dayvigo

Wisconsin Medicaid (ForwardHealth) covers Dayvigo with a prior authorization requirement. That means your prescribing clinician must submit clinical documentation showing that you have a diagnosis of chronic insomnia disorder and that at least one formulary-preferred agent has been tried and found inadequate or contraindicated. Preferred agents on the Wisconsin ForwardHealth preferred drug list have historically included generic zolpidem and doxepin at sedating doses, so expect your PA submission to address those alternatives. Wisconsin ForwardHealth pharmacy benefit policies are published by the Wisconsin Department of Health Services.

Prior authorization approval timelines vary. Standard PA requests in Wisconsin typically resolve within 3 business days under ForwardHealth rules; urgent PA requests must be answered within 24 hours. If approved, Medicaid covers up to a 30-day supply per fill with authorized refills. Your copay as a Wisconsin Medicaid member is generally $3 or less per prescription. The Centers for Medicare and Medicaid Services publishes state Medicaid drug coverage frameworks at CMS.gov, and Wisconsin must comply with federal upper-payment and PA transparency standards under the Medicaid Drug Rebate Program.

Dual-eligible patients (Medicare plus Wisconsin Medicaid) should check their Part D plan formulary separately. Dayvigo appears on some Part D formularies at Tier 3 or Tier 4, with monthly cost-sharing between $40 and $100 depending on plan design.

Which Private Insurance Plans Cover Dayvigo in Wisconsin

Most commercial insurance plans sold in Wisconsin place Dayvigo on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier placement determines cost-sharing. At Tier 3, a 30-day supply typically runs $40 to $75 after deductible; at Tier 4, $70 to $120 is common. The Academy of Managed Care Pharmacy notes that orexin receptor antagonists as a class face non-preferred placement on roughly 60% of commercial formularies nationally.

Employer-sponsored plans administered in Wisconsin by Anthem, Quartz, Security Health Plan, Dean Health Plan, Common Ground Healthcare Cooperative, and National Government Services each maintain independent formularies. Step-therapy requirements are common: you may need to document a trial of generic zolpidem (typically 7 to 30 days) before the plan will approve Dayvigo at a preferred tier. The AMA has published guidance on step-therapy override protections, and Wisconsin enacted step-therapy reform language in 2022 requiring commercial insurers to permit override requests when a preferred agent causes harm or is contraindicated.

Always verify the specific formulary year. Plan formularies reset January 1 each year, and tier assignments for Dayvigo may shift mid-year if Eisai renegotiates contracts. The most current tier and PA requirements appear in your plan's Summary of Benefits and Coverage or its online formulary search tool.

The Eisai Patient Savings Card: How It Works in Wisconsin

Eisai operates a co-pay assistance program for commercially insured patients. Information about the Dayvigo savings program is available directly through Eisai's patient support portal. The card reduces out-of-pocket cost to as low as $0 for eligible patients with commercial insurance. Key eligibility constraints apply: the card cannot be used by patients enrolled in any federal or state government insurance program, which means it is not available to Wisconsin Medicaid, Medicare, or BadgerCare Plus members. Income limits may apply and the program terms change annually, so confirm current eligibility on the Eisai website before assuming coverage.

For patients who qualify, the savings card functions like a secondary payer at participating pharmacies. The pharmacy runs your commercial insurance first, then applies the Eisai card to the remaining balance. The card typically covers up to a set annual maximum (historically $3,600 per calendar year), after which you revert to standard commercial cost-sharing. The FDA's guidance on manufacturer copay assistance programs and their interaction with insurance is outlined in agency communications on drug pricing transparency.

Is Compounded Lemborexant Legal in Wisconsin?

Compounded lemborexant is legally dispensed in Wisconsin through state-licensed 503A compounding pharmacies, subject to specific conditions. A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act and compounds medications for individual patients pursuant to a valid prescription from a licensed practitioner. The FDA's framework for 503A compounding pharmacies is detailed in FDA guidance documents.

Because lemborexant is a Schedule IV controlled substance under the DEA, any 503A pharmacy dispensing compounded lemborexant must hold both a state pharmacy license from the Wisconsin Pharmacy Examining Board and a DEA registration. DEA requirements for controlled substance compounding are outlined in the DEA Practitioner's Manual. The prescribing clinician must also hold a valid DEA registration and may only prescribe Schedule IV controlled substances in Wisconsin within the scope of a valid prescriber-patient relationship.

Cost for compounded lemborexant from a 503A pharmacy can be substantially lower than the branded product, with some compounding pharmacies pricing a 30-day supply at near-zero to patients when dispensed under certain membership or telehealth-bundled arrangements. However, compounded preparations are not FDA-approved. They are not required to demonstrate bioequivalence to Dayvigo, and quality may vary between compounding pharmacies. The FDA has published consumer guidance on the differences between compounded and FDA-approved drugs.

Wisconsin does not prohibit compounding of Schedule IV substances, but the Wisconsin Pharmacy Examining Board reserves the right to inspect and audit compounding operations. Patients should request a certificate of analysis (COA) for any compounded lemborexant preparation before use. The National Association of Boards of Pharmacy (NABP) maintains a list of accredited compounding pharmacies.

A practical framework for Wisconsin patients evaluating the compounding option: (1) Confirm your prescriber holds a current DEA registration and is licensed in Wisconsin. (2) Verify the compounding pharmacy holds both a Wisconsin Pharmacy Examining Board license and a Schedule IV DEA registration. (3) Request a COA showing potency, sterility (if applicable), and absence of contaminants. (4) Clarify whether your telehealth platform has a direct relationship with the dispensing pharmacy, which may affect pricing. (5) Understand that your Wisconsin Medicaid or commercial insurance will not reimburse compounded lemborexant, because compounded drugs lack NDC numbers required for insurance billing.

The Clinical Evidence Behind Lemborexant

Understanding what you are paying for matters. Lemborexant is a dual orexin receptor antagonist (DORA) that blocks OX1R and OX2R receptors, reducing wake-promoting orexin signaling to allow sleep onset and maintenance. The mechanism is described in detail in the SUNRISE-1 trial publication.

SUNRISE-1 (N=1,006, JAMA Network Open 2019) was the key Phase 3 trial comparing lemborexant 5 mg and 10 mg versus placebo and versus zolpidem extended-release 6.25 mg over 30 nights in adults with insomnia disorder. SUNRISE-1 showed that lemborexant 5 mg reduced subjective sleep onset latency by 16.7 minutes and lemborexant 10 mg by 18.0 minutes versus 9.1 minutes for zolpidem ER and 7.4 minutes for placebo at month 1. Both lemborexant doses produced statistically significant improvements over zolpidem ER on subjective sleep onset latency (P<0.001). This head-to-head comparison is one reason clinicians and formulary committees consider Dayvigo a meaningful advance over older hypnotics.

SUNRISE-2 (N=949) extended the comparison over 12 months and was published in Sleep Medicine. SUNRISE-2 data showed sustained efficacy for lemborexant with no evidence of tolerance development over 52 weeks. That long-term data set is relevant to insurance PA submissions: demonstrating that a patient has chronic, not transient, insomnia supports medical necessity arguments.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline for chronic insomnia in adults lists pharmacotherapy, including newer DORA agents, as a recommended treatment when combined with cognitive behavioral therapy for insomnia (CBT-I). The AASM guideline states: "We recommend that clinicians use CBT-I as the initial treatment for chronic insomnia disorder in adults. When pharmacologic therapy is indicated, clinicians may consider the use of suvorexant, low-dose doxepin, or other agents based on individual patient factors." Lemborexant's clinical profile, including lower morning residual sedation versus zolpidem ER on lane-deviation driving tests, may strengthen a PA argument for patients who failed or had side effects from older agents. The driving performance comparison was assessed in a crossover study published in Sleep Medicine.

Telehealth Prescribing of Dayvigo in Wisconsin

Wisconsin law permits telehealth prescribing of Dayvigo under the same rules that govern in-person prescribing, with one important federal overlay. Because lemborexant is a Schedule IV controlled substance, the Ryan Haight Online Pharmacy Consumer Protection Act historically required an in-person evaluation before the first controlled substance prescription via telemedicine. The DEA's Special Registration rule has been under development since 2023 to create a formal telehealth pathway; as of the 2025 to 2026 period, the DEA continues to operate under COVID-era telemedicine flexibility extensions that permit clinicians registered with the DEA to prescribe Schedule IV substances via telehealth without a prior in-person visit, provided they meet documentation standards. DEA telemedicine regulations and current flexibilities are tracked on the DEA Diversion Control Division website.

Wisconsin telehealth statute (Wis. Stat. sec. 448.9725) requires that a valid prescriber-patient relationship be established before any prescription is issued via telehealth. For insomnia, this means a synchronous audio-video visit that includes a sleep history, review of prior treatment trials, and assessment for contraindications including concurrent CNS depressants or severe hepatic impairment. Wisconsin telehealth prescribing standards are outlined in Wisconsin Statutes Chapter 448.

HealthRX clinicians licensed in Wisconsin can prescribe Dayvigo or, where clinically appropriate and legally permissible, compounded lemborexant following a synchronous video intake visit. The prescribing clinician reviews sleep onset latency, wake after sleep onset history, prior hypnotic trials, and current medication list before any prescription is sent to a Wisconsin-licensed pharmacy.

Side Effects and Contraindications Relevant to Wisconsin Patients Considering Cost vs. Benefit

Cost analysis only makes sense alongside clinical appropriateness. Lemborexant is contraindicated in patients with narcolepsy, per the FDA label. The Dayvigo prescribing information lists complex sleep behaviors (sleep-walking, sleep-driving) as serious risks requiring discontinuation if they occur. Dose adjustment to 5 mg is required for patients taking moderate CYP3A inhibitors; use with strong CYP3A inhibitors is not recommended. Severe hepatic impairment is a contraindication.

Common adverse effects in SUNRISE-1 included somnolence (10% at 10 mg versus 1% placebo), headache (6% versus 7%), and dizziness (4% versus 1%). Adverse event rates from SUNRISE-1 are reported in the JAMA Network Open publication. Next-morning impairment is lower with lemborexant than zolpidem ER based on the driving simulation data, but patients should not drive or operate machinery if they feel impaired the morning after a dose. The FDA's drug safety communication on hypnotic-related impaired driving reinforces this caution.

For older adults, SUNRISE-1 included a subgroup age 65 and older. The 5 mg dose is preferred in this population given falls risk, and the AASM guideline supports dose minimization in elderly patients. The American Geriatrics Society Beers Criteria for potentially inappropriate medications notes that orexin receptor antagonists may be preferable to benzodiazepines and Z-drugs in older adults.

Comparing Your Cost Options Side by Side

Wisconsin patients filling a Dayvigo prescription in 2026 have at least four distinct cost pathways. The branded cash price without any assistance runs approximately $320 per month at list. With a GoodRx or similar discount applied at a Wisconsin retail pharmacy, that drops to approximately $85 per month. Commercially insured patients with the Eisai savings card may pay $0 per month up to the annual card maximum. Wisconsin Medicaid members who obtain prior authorization pay $3 or less per fill. And patients obtaining compounded lemborexant from a licensed 503A pharmacy under a telehealth prescription pay approximately $0 per month in pharmacy cost, though a telehealth visit fee may apply. The FDA's framework for understanding brand versus compounded drug options is available on the FDA website.

Each pathway has trade-offs. The branded product carries FDA approval and a defined quality standard. The FDA approval of Dayvigo is documented in the agency's drug database. Compounded preparations may be less expensive but require patient diligence in verifying pharmacy credentials. Insurance coverage reduces monthly cost but requires step-therapy compliance and PA paperwork that adds clinician time. The right pathway depends on your insurance status, prior treatment history, and clinical profile.

Telehealth-based insomnia care in Wisconsin typically begins with a 20 to 40 minute video intake visit. The American Academy of Sleep Medicine has published telehealth guidance for sleep disorders. If Dayvigo is appropriate and prior authorization is needed, the clinician submits documentation of insomnia chronicity, prior treatment failures, and absence of contraindications. Approval typically takes 3 to 5 business days for commercial plans and up to 3 business days for ForwardHealth.

Start the prior authorization process before your first prescription runs out. Wisconsin ForwardHealth allows retroactive PA in limited circumstances, but commercial insurers rarely do.